Clinical Trials Browser

Recurrence × Sorafenib × Dermatologic × Clear all

NCT01851408 2015-04-15

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Phase 2 Withdrawn

Melanoma, Recurrence